Výsledky vyhledávání - "Dana Parsons‐Rich"

Akademický článek

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial

Autor: Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era

Publikováno v: ACR Open Rheumatology, Vol 5, Iss 1, Pp 38-48 (2023)

Objective Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of

Externí odkaz: https://doaj.org/article/fbfb7923863e4170999f2062f9b263dc

Zobrazit plný text záznamu

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II , Randomized, Double‐Blind , Placebo‐Controlled Dose‐Ranging Trial

Autor: Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era

Publikováno v: ACR Open Rheumatology. 5:38-48

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b9466da0aa9a79b3ec812df5812e5ab
https://doi.org/10.1002/acr2.11511

Zobrazit plný text záznamu

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial

Autor: Daniel J, Wallace, Thomas, Dörner, David S, Pisetsky, Jorge, Sanchez-Guerrero, Anand C, Patel, Dana, Parsons-Rich, Claire, Le Bolay, Elise E, Drouin, Amy H, Kao, Hans, Guehring, Maria, Dall'Era

Publikováno v: ACR open rheumatologyREFERENCES.

Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double-blind, placebo-controlled trial was to evaluate the efficacy and safety of evobrutinib in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8c914e887bef8a0fc2d37ee1efc59306
https://pubmed.ncbi.nlm.nih.gov/36530019

Zobrazit plný text záznamu

Phase 1 dose‐escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)

Autor: Dana Parsons-Rich, Debra D. Pittman, Steven Arkin, Constantino Kantaridis, Gang Li, Fei Hua

Publikováno v: Journal of Thrombosis and Haemostasis. 15:931-937

Essentials FXaI16L is a recombinant zymogen-like variant of activated coagulation factor X (FXa). A phase 1 dose escalation clinical trial of FXaI16L was conducted in healthy adults. FXaI16L was safe and tolerated at doses up to 5 μg/kg; no dose-lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4468cd8fcade323846621d76ee09528e
https://doi.org/10.1111/jth.13673

Zobrazit plný text záznamu

Escalating Single Doses of PF-05230907 (Recombinant Factor Xa Variant FXaI16L) Are Safe and Demonstrate Hemostatic Pharmacology in Healthy Volunteers

Autor: Gang Li, Constantino Kantaridis, Fei Hua, Dana Parsons-Rich, Debra D. Pittman, Steven Arkin

Publikováno v: Blood. 128:3781-3781

PF-05230907 (FXaI16L) is a zymogen-like variant of recombinant activated coagulation factor X (FXa), which is more resistant to inactivation by plasma protease inhibitors (compared to endogenous FXa). Previous studies showed that its cofactor, Factor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8610d39a66b0b2aa29398f5d73354b54
https://doi.org/10.1182/blood.v128.22.3781.3781

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání